WestlawNext Canada insight Blog

News and Views — WeirFoulds Estates & Trusts Newsletter

by Farah Malik


See the Estates&TrustsSource Advantage for yourself

Cuthbertson v. Rasouli and its Implications for Substitute Decision-Makers

 

        In a much-anticipated judgment decided last week, the Supreme Court of Canada in Cuthbertson v. Rasouli confirmed that withdrawing or withholding life support constitutes treatment which, in turn, requires consent from a patient or substitute decision-maker under Ontario’s Health Care Consent Act, 1996 (“HCCA”).  

        Hassan Rasouli, by his litigation guardian, substitute decision-maker and wife Parichehr Salasel, applied for a Court order preventing withdrawal of his life-sustaining treatment at Sunnybrook Health Sciences Centre.  This treatment, which consists of the use of a mechanical ventilator and feeding tube, was implemented as a result of severe brain injury following the removal of a benign tumour in Mr. Rasouli’s head.  Mr. Rasouli has been on life support since October of 2010. 

        The respondent doctors responsible for Mr. Rasouli’s care cross-applied for a declaration that consent is not required to withdraw life-sustaining treatment where such treatment is not medically indicated.  More particularly, they argued that they have unilateral discretion to withdraw Mr. Rasouli’s life support because his persistent vegetative state (“PVS”) means that he will never again regain consciousness; all appropriate treatments have been exhausted; and the life-sustaining measures at issue are no longer medically effective, i.e. there is no realistic hope of recovery.   The respondent doctors proposed, instead, to remove Mr. Rasouli’s life support and provide him with palliative care until he dies. 

        While capable, Mr. Rasouli did not express any wishes regarding removal or continuation of life support, although the evidence did indicate that his Shiite Muslim beliefs about the end of life ought to be taken into account.

        In a split 5-2 decision, the Supreme Court dismissed the respondent doctors’ appeal, finding that consent is indeed required under the HCCA to withdraw life support. Because the substitute decision-maker in this case refused to provide her consent to the withdrawal of Mr. Rasouli’s life support, the respondent doctors’ were required to challenge her decision before the Consent and Capacity Board (“CCB”).

        The majority of the Supreme Court began its analysis by recognizing that the HCCA is premised on the general public policy rule that medical treatment cannot be administered without consent.

        The primary legal issue before the Rasouli Court, therefore, was whether the defined term “treatment” under the HCCA could include a decision to terminate or withdraw life support where a patient is terminally ill or has little chance of survival without such support. 

        The term “treatment,” in turn, is broadly defined as “anything that is done for a therapeutic, preventive, palliative, diagnostic, cosmetic or other health-related purpose” (emphasis added).  The majority found that life support serves a “health-related purpose” by preventing suffering and indignity at the end of life.  Because the withdrawal of life support also involves physical interference with a patient’s body, the majority rejected the respondent doctors’ argument that a “health-related purpose” is limited to what an attending physician considers to medically benefit a patient. 

        The majority also found that life support arguably falls within the ambit of “therapeutic” and “preventive” purposes within the definition of “treatment”, i.e. life support could have the effect of keeping a patient alive and forestalling death.

 

        More importantly, the majority recognized that withdrawing life support from someone like Mr. Rasouli “impacts patient autonomy in the most fundamental way.”

        The Supreme Court agreed that because “treatment” includes the withdrawal of life support, Ontario health practitioners cannot act unilaterally in doing so, i.e. they must obtain consent to do so from patients or their substitute decision-makers.  If disputes between health practitioners and next-of-kin substitute decision-makers arise over consent regarding life support, resort should be had to the CCB, an “independent, quasi-judicial body with specialized jurisdiction over matters of consent to medical treatment” for a full consideration of the incapable person’s best interests.

        In light of Rasouli, attorneys for personal care, as well as spouses, children, parents and other close relatives of capable patients over the age of 16, should keep the following in mind:

1. If capable patients are slated to undergo risky medical procedures that could result in death, serious injury, or a PVS, attempts should be made to determine the wishes of such patients respecting life support and end-of-life palliative care.  While such discussions can be extremely difficult to have, they should nevertheless take place to avoid needless litigation.  A capable patient’s wishes should be documented in writing and witnessed wherever possible to preserve his or her dignity and autonomy.   This is also because prior capable wishes, arising from different contexts, will not be applied mechanically.   The question will be whether when the wish was expressed, the patient intended its application in his or her present circumstances.

2. If a patient’s wishes are not discernable for capacity or other reasons, attorneys for personal care or close family members should nevertheless ascertain the patient’s general values and beliefs, especially with respect to prolonged life-sustaining measures.   In providing or refusing consent to life-sustaining measures, a substitute decision-maker must take into account the patient’s best interests, which include his or her value and belief system, as well as the patient’s overall medical state and well-being.

 

© Copyright Westlaw Canada, Thomson Reuters Canada Limited. All rights reserved.